Actively Recruiting
Phase I Clinical Trial to Assess Safety, Pharmacokinetics, and Antitumor Activity of JSKN021 in Adults with Advanced Malignant Solid Tumors
Led by Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Updated on 2026-08-26
199
Participants Needed
10
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase I, open-label clinical trial to assess the safety, tolerability, pharmacokinetics, and early antitumor effects of the drug JSKN021 in adults with advanced malignant solid tumors. This first-in-human study aims to understand how JSKN021 behaves in the body and its potential impact on tumors in patients who have not responded to or cannot access standard treatments. Participants will receive JSKN021 intravenously at various dose levels across multiple sequential cohorts, including dose escalation and dose optimization groups. The study will monitor for adverse events, determine the optimal biological dose, and evaluate preliminary tumor responses over a period that may extend up to 24 months. During the trial, participants will have regular visits for treatment administration and safety assessments, including laboratory tests and imaging to measure tumor response. Researchers will track treatment-emergent side effects, dose-limiting toxicities, pharmacokinetic parameters, and survival outcomes. Participants are expected to comply with all study procedures and follow-up visits throughout the study duration.
CONDITIONS
Brief Title
A Phase I Study of JSKN021 in Advanced Solid Tumors
Research Team
J
Jian Zhang, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here